We are a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. In this stock guide, we will share with you 4 reasons to buy and 4 reasons to sell ACAD stock. ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results July 31, 2019 ACADIA Pharmaceuticals Inc. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. and hear what the. ETF market. ACADIA Pharmaceuticals Inc. 05:46 PM ET. Get breaking news and analysis on ACADIA Pharmaceuticals Inc. Community Stock Ratings for ACADIA Pharmaceuticals Inc. Benzinga 528d. ACADIA Pharmaceuticals Inc. Acadia Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 76 to 85 Tuesday. 57 and a beta of 2. The ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results. Acadia Pharmaceuticals Inc. Advanced Chart, Quote and financial news from the leading provider and award-winning BigCharts. In general, biotechnology stocks tend to carry a higher short ratio. S-3ASR S-3ASR. ACADIA Pharmaceuticals Inc. Start a 14-day free trial to Morningstar Premium to unlock our take on ACAD. Find out the direct holders, institutional holders and mutual fund holders for ACADIA Pharmaceuticals Inc. NEW YORK ( TheStreet) -- ACADIA Pharmaceuticals (Nasdaq: ACAD) has been downgraded by TheStreet Ratings from hold to sell. Only one blue-chip stock on this. (ACAD) stock including calls, puts, option quotes, implied volatility, option greeks, option trade details, option open interest and more. 00 price objective on ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research note published on Wednesday, TipRanks reports. The culprit? Sales of the company's Parkinson. 1% rise to close the regular session at $25. However, the stock crashed by 15. The higher this short ratio, the more investors are expecting that the stock is going to fall. Our mission is to extend and improve the quality of life for cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the. (ACAD) stock value sealed its day with gain 2. Ferring Pharmaceuticals is devoted to identifying, developing and marketing innovative products in reproductive and maternal health, urology, gastroenterology, endocrinology and orthopaedics. But more than that, you probably want to see it rise more than the market average. Common Stock Common Stock (ACAD) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Information about facility, team, and investors. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. Street forecast for the quarter ending June 2019 is $-0. 41% so far in today's session. Updated stock price target summary. 67 and a one-year low of $12. About ACADIA Pharmaceuticals ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system. (ACAD)'s Stock Price Update: ACADIA Pharmaceuticals Inc. , Novartis AG, Teva Pharmaceutical Industries Ltd. View the real-time ACAD price chart on Robinhood and decide if you want to buy or sell commission-free. , August 13, 2019 — AMAG Pharmaceuticals, Inc. (ACAD) by investors and analysts. Acadia Pharmaceu (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $27. (NASDAQ:ACAD) will report ($0. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Approximately 2,628,693 shares changed hands during mid-day trading, an increase of 76% from the average daily volume of 1,490,556 shares. (ACAD) shares dropped in the extended session Monday after the biotech drug maker said its schizophrenia treatment did not pass a late-stage clinical trial. (NASDAQ: ACAD) fell 13. DOW JONES, A NEWS CORP COMPANY News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. We are building a rewarding place to work where people are empowered to make a difference and where diversity of backgrounds and ideas is encouraged. Company Releases for ACADIA Pharmaceuticals Inc. com's stock comparison tool. We are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the CNS area. ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia. ACADIA Pharmaceuticals, Inc. S-3ASR S-3ASR. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACADIA PHARMACEUTICALS INC. 1% as of 12:00 p. 57 and a beta of 2. At Stock Options Channel, our YieldBoost formula has looked up and down. 61 million shares, as the stock started the trading session at the value of $29. View the latest stock recommendations for ACADIA Pharmaceuticals Inc. is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. The Southern Investigative Reporting Foundation's. Predict and forecast ACAD (Acadia Pharmaceuticals Inc) plus see real-time data from other investors. August 02, 2019. Acadia stock drops as schizophrenia drug doesn't pass clinical trial ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for. and all the companies you research at NASDAQ. The summary for ACADIA PHARMACEUTICALS INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Common Stock Common Stock (ACAD) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. View today's stock price, news and analysis for ACADIA Pharmaceuticals Inc. Acadia Healthcare's behavioral health treatment facilities are specialized in helping children, adolescents, adults and seniors suffering from mental health disorders and / or alcohol and drug addiction. At ACADIA, we are passionate about improving the lives of patients with central nervous system (CNS) disorders. Analyst Ratings For ACADIA Pharmaceuticals Inc. Technical chart claims that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report sales of $73. View detailed financial information, real-time news, videos, quotes and analysis on ACADIA Pharmaceuticals Inc. Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock: 1. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. 23 million shares, ACADIA Pharmaceuticals (ACAD) recorded a trading volume of 1. View ACADIA Pharmaceuticals Inc. 42 for its downside target. securities class action lawsuit. According to analysts polled by Zacks Research, the current average broker rating on shares of ACADIA Pharmaceuticals Inc. There are 7. ACADIA Pharmaceuticals Inc. Actinium is developing a pipeline Antibody Radiation Conjugates for targeted conditioning and combination therapies. Get detailed information about the ACADIA Pharmaceuticals Inc (ACAD) stock including price, charts, technical analysis, historical data, ACADIA reports and more. Acadia Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90. boosted its position in ACADIA Pharmaceuticals Inc. 61 million for the current quarter, according to Zacks Investment Research. 35 and a debt-to-equity ratio of 0. Read more about Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference June 28, 2019 Allena Pharmaceuticals Announces $10. (NASDAQ:ACAD) rose 7. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS. ACADIA Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $41. ACADIA Pharmaceuticals Inc. Serious investors discussing stocks, stock research and stock market news. com reports. Glassdoor has 8 ACADIA Pharmaceuticals reviews submitted anonymously by ACADIA Pharmaceuticals employees. Sales of nuplazid — Acadia’s only drug on the market — rose 37 percent year-over-year to $59. (ACAD) is making a move up in the market today. For more than 30 years, the Medical Technology Stock Letter (MTSL) has provided independent investment advice based on rigorous analysis of emerging biotechnology companies and a unique perspective on industry fundamentals. ACADIA Pharmaceuticals has a 52 week low of $12. 97/share level. Morgan also maintained a Buy rating on the stock. In depth view into ACAD (ACADIA Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. co/ZkzlOds4Fs August 9 th 2019, 10:08am. Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock quote, history, news and other vital information to help you with your stock trading and investing. Keith Speights. ACAD | Complete ACADIA Pharmaceuticals Inc. At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results. We are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the CNS area. In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicine for cancer. ACADIA Pharmaceuticals (NASDAQ: ACAD) stock soared 5% in the after-market trading hours as the biopharma firm reported better-than-expected Q2 results. The high price target for ACAD is $60. However, we also tend to see quite a few short squeezes in the sector. Street forecast for the quarter ending June 2019 is $-0. Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment. (NASDAQ:ACAD) rose 7. Compared to these stocks ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Acadia Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 90 to 95. Acadia has risks which investors need to consider in connection with their commitment to this stock. View our complimentary trend analysis for ACADIA Pharmaceuticals, Inc (ACAD) now. 69 for its downside target. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 16,176,471 shares of its common stock, offered at a price to. Arbor also has several branded prescription products in late-stage development. 39 on Friday. Read more about Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference June 28, 2019 Allena Pharmaceuticals Announces $10. The company traded as high as $26. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. Acadia Healthcare Company is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals Inc. Compared to these stocks ACADIA Pharmaceuticals Inc. We are building the foundation to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the CNS area. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated. ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related. 53% of gains with the last five trading sessions. EST on extremely heavy volume. Stock quote for ACADIA Pharmaceuticals Inc. On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. ACADIA Pharmaceuticals Q4 Earnings Preview. In this stock guide, we will share with you 4 reasons to buy and 4 reasons to sell ACAD stock. Don't miss ACAD stock next rating changes. ACAD Securities Fraud Legal Help If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible ACADIA Pharmaceuticals Inc. 2%, which took the trading range below the 3-day low of. No Buyout just to buy back at bear market prices when everyone else is selling on the news. and hear what the. It's free, It's informative, It's on the money. PEOPLE We bring together scientists, drug developers, and business leaders who share the same focus on curing some of the most debilitating diseases of our time. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. In this stock guide, we will share with you 4 reasons to buy and 4 reasons to sell ACAD stock. Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for. Keith Speights. When a pharmaceutical company has a setback in a late-stage trial with regards to one of their products, it can trigger extreme distress to its stock. 87, which is 1. (ACAD) would settle between $23. ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. The drugmaker's shares perked up in late February after the release of its upbeat fourth-quarter and full. Information about facility, team, and investors. View a comprehensive option chain for Acadia Pharmaceuticals Inc. Food and Drug Administration. 04-24 zacks. (ACAD) stock price ended its day with loss -1. PEOPLE We bring together scientists, drug developers, and business leaders who share the same focus on curing some of the most debilitating diseases of our time. (NASDAQ: ACAD) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and. Acadia Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 90 to 95. Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biopharma, continued its recent rebound last month as its stock gained a healthy 16. SVP, Investor Relations Elena. Stock Score Report, InvestorsObserver's proprietary scoring system, gives ACAD stock a score of 45 out of a possible 100. ACADIA Pharmaceuticals Inc. 18% from its latest closing price when compared to the 1-year high value of $28. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to announce $88. Five analysts have made estimates for ACADIA Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $85. audiences only. , the stock’s short ratio clocks in at 11. operates as a biopharmaceutical company focuses on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system. Five analysts have provided estimates for ACADIA Pharmaceuticals' earnings, with estimates ranging from $69. (NASDAQ:ACAD) to $34. -traded ETFs. 26 and last traded at $25. (NASDAQ:ACAD) to report sales of $73. (NAS: ACAD) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to. 61 million for the current quarter, according to Zacks Investment Research. (ACAD) stock quote, history, news and other vital information to help you with your stock trading and investing. (NASDAQ:ACAD) went down by -0. Benzinga 528d. Barron's also provides information on historical stock ratings, target prices, company earnings, market. 61 million shares, as the stock started the trading session at the value of $29. 6M shares in the U. A Highly Focused Generics and Specialty Branded Pharmaceutical Company. What's going on? The company's fourth-quarter sales of its drug for Parkinson's. from Investor's Business Daily. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. also maintained a Buy rating on the stock with a $42 price target. Acadia Pharmaceuticals Description Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. MELINTA THERAPEUTICS, INC. Acadia stock drops as schizophrenia drug doesn't pass clinical trial ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for. Analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals Inc today and set a price target of $42. X When you're researching the best stocks to buy and watch, be sure to pay. View the latest ACAD stock quote and chart on MSN Money. Revenue grew 45. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a. No Buyout just to buy back at bear market prices when everyone else is selling on the news. On the day, ACADIA Pharmaceuticals Inc. NEWS: Buy Acadia Pharmaceuticals Best Biotech Earnings Report. View ACAD stock price today, real time quote with excellent interactive chart, get the latest alerts for ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS. ACADIA Pharmaceuticals Inc. Disclosure: None. Achillion Pharmaceuticals. (NASDAQ: ACAD) shares dipped on Wednesday despite the announcement of positive top-line results from its Clarity midstage study in major depressive disorder (MDD). (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other. Check out these big penny stock gainers and losers. We are building a rewarding place to work where people are empowered to make a difference and where diversity of backgrounds and ideas is encouraged. Let our Trade Triangle technology, brought to you courtesy of our premium service MarketClub, instantly analyze any stock, futures or forex market for you. Add a live ACAD stock price to your free portfolio. -traded ETFs. Acadia Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 76 to 85 Tuesday. 5% upside from current levels. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. (ACAD) by investors and analysts. (ACAD) would settle between $23. Technical chart claims that ACADIA Pharmaceuticals Inc. But more than that, you probably want to see it rise more than the market average. Several other analysts also recently issued reports on ACAD. The company also lifted its sales outlook, which surpassed estimates. Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS. (NASDAQ:ACAD). ABIO ARCA biopharma, Inc. ACADIA Pharmaceuticals Inc. Analyze performance using advanced charting and trend analysis. 8% over the last 12 months, and the average rating from Wall Street analysts is a Moderate Buy. Our discovery programs are at an early stage of development and we are dependent on securing additional funding from both current and new collaborations to meet our future funding requirements. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio. No Buyout just to buy back at bear market prices when everyone else is selling on the news. Stock quote for ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. ACAD investment & stock information. SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. About ACADIA Pharmaceuticals ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system. S-3ASR S-3ASR. At Walletinvestor. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. Real-time trade and investing ideas on ACADIA Pharmaceuticals, Inc. Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for. with InvestorGuide. On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA Pharmaceuticals (NASDAQ: ACAD) stock soared 5% in the after-market trading hours as the biopharma firm reported better-than-expected Q2 results. stock market and it is a holding in 53 U. ValuEngine downgraded ACADIA Pharmaceuticals from a. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. ACAD has around 14. Any clue why there is so much of action in the ACAD stock? The share price has risen in 2 of the last 5 days and is up 6. actelion pharmaceuticals us, inc. (NASDAQ: ACAD) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and. (NASDAQ:ACAD) stock was falling hard today on an article about its drug Nuplazid. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. 70 million and the highest estimate coming in at $91. Sell-side analysts have the capability of providing stock ratings for companies that they cover. Regeneron Pharmaceuticals, Inc. TD Asset Management Inc. The price of one share of stock, which is set by buyers and sellers in the market. 10 Wall Street analysts have issued ratings and price targets for ACADIA Pharmaceuticals in the last 12 months. , Merck and Co. Welcome to Ligand Pharmaceuticals. At Stock Options Channel, our YieldBoost formula has looked up and down. The company has a market cap of $3. In depth view into ACAD (ACADIA Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. (ACAD) - See ratings for ACAD from other NASDAQ Community members and submit your own rating for ACAD. Acadia Pharmaceuticals Description Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. 00 price objective on ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research note published on Wednesday, TipRanks reports. We are a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. (NASDAQ:ACAD) rose 7. is a company in the U. Doctors and other experts tell CNN they worried that a new drug, Nuplazid, aimed at treating Parkinson's disease patients with hallucinations was approved too quickly. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. (NASDAQ: ACAD) fell 13. ACADIA Pharmaceuticals Inc. 23% in today's trading session, a rise equivalent to 4. Five analysts have made estimates for ACADIA Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $85. Technical chart claims that ACADIA Pharmaceuticals Inc. 's (ACAD) stock price could be set to double as analysts forecast soaring revenue in the near future. Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment. ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by Raymond James from $40. 14, its 52 week- peak value and changed 96. Actelion`s corporate responsibility covers efforts from employee development and diversity, to governance and ethics, as well as the organization’s economic, environmental, and social performance. ACADIA Pharmaceuticals Inc. Achillion Pharmaceuticals. At ACADIA, we are passionate about improving the lives of patients with central nervous system (CNS) disorders. Why Acadia Pharmaceuticals Stock Is Crashing Today. Are you looking for the analysis of ACADIA Pharmaceuticals Inc. I've been keeping an eye on ACADIA Pharmaceuticals Inc. On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Real-time trade and investing ideas on ACADIA Pharmaceuticals, Inc. 38 after jumping by 1. Acadia Pharmaceuticals Description Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. company facts, information and stock details by MarketWatch. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. 1% as of 12:00 p. NasdaqGS - NasdaqGS Real-time price. Acadia Pharmaceuticals (NASDAQ: ACAD), a company developing novel treatments for disorders of the central nervous system, saw its shares fall by a noteworthy 17. On Tuesday, September 25, Acadia Pharmaceuticals stock closed at $21. Share your opinion and gain insight from other stock traders and investors. Start a 14-day free trial to Morningstar Premium to unlock our take on ACAD. ACADIA Pharmaceuticals Inc. Acerus is a specialty pharmaceutical company focused on the commercialization and development of innovative products that improve the patient experience. ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals, Inc. Acadia Pharmaceuticals Description Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. Find the latest ACADIA Pharmaceuticals Inc. MELINTA THERAPEUTICS, INC. (NASDAQ:ACAD) last week. On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Information about facility, team, and investors. Get the latest Acadia Pharmaceuticals Inc. The company also lifted its sales outlook, which surpassed estimates. Wall Street brokerages expect ACADIA Pharmaceuticals Inc. View acad business summary and other industry information. (NAS: ACAD) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28. On Tuesday, September 25, Acadia Pharmaceuticals stock closed at $21. co/ZkzlOds4Fs August 9 th 2019, 10:08am. ACADIA Pharmaceuticals Inc. Rexahn Pharmaceuticals Inc. and its affiliates, Regeneron Ireland Unlimited Company and Regeneron UK Limited (together, "Regeneron", "we", "us" or "our") use this data to make the Sites more user-friendly and efficient. The company's shares opened today at $28. Find the latest ACADIA Pharmaceuticals Inc. 23 million shares, ACADIA Pharmaceuticals (ACAD) recorded a trading volume of 1. stock market and it is a holding in 53 U. Real-time trade and investing ideas on ACADIA Pharmaceuticals, Inc. ACADIA Pharmaceuticals, Inc. 13M shares by far recorded in the movement of ACADIA Pharmaceuticals (ACAD). Get the latest ACADIA Pharmaceuticals Inc. company facts, information and stock details by MarketWatch. (ACAD) stock quote, history, news and other vital information to help you with your stock trading and investing. is a biopharmaceutical company. 97/share level. Yesterday, Acadia Pharmaceuticals closed at $25. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis).